| A win–win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane … JM Miller, A Beig, RA Carr, JK Spence, A Dahan Molecular pharmaceutics 9 (7), 2009-2016, 2012 | 268 | 2012 |
| The solubility–permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation JM Miller, A Beig, BJ Krieg, RA Carr, TB Borchardt, GE Amidon, ... Molecular pharmaceutics 8 (5), 1848-1856, 2011 | 206 | 2011 |
| The solubility–permeability interplay and oral drug formulation design: Two heads are better than one A Dahan, A Beig, D Lindley, JM Miller Advanced drug delivery reviews 101, 99-107, 2016 | 172 | 2016 |
| The solubility–permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations JM Miller, A Beig, RA Carr, GK Webster, A Dahan Molecular pharmaceutics 9 (3), 581-590, 2012 | 142 | 2012 |
| Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations A Beig, R Agbaria, A Dahan PLoS One 8 (7), e68237, 2013 | 119 | 2013 |
| Accounting for the solubility–permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption A Beig, JM Miller, A Dahan European journal of pharmaceutics and biopharmaceutics 81 (2), 386-391, 2012 | 116 | 2012 |
| Head-to-head comparison of different solubility-enabling formulations of etoposide and their consequent solubility–permeability interplay A Beig, JM Miller, D Lindley, RA Carr, P Zocharski, R Agbaria, A Dahan Journal of pharmaceutical sciences 104 (9), 2941-2947, 2015 | 82 | 2015 |
| In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: Investigation of the single-pass vs. the Doluisio experimental approaches I Lozoya-Agullo, M Zur, O Wolk, A Beig, I González-Álvarez, ... International journal of pharmaceutics 480 (1-2), 1-7, 2015 | 81 | 2015 |
| The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane A Dahan, A Beig, V Ioffe-Dahan, R Agbaria, JM Miller The AAPS journal 15, 347-353, 2013 | 80 | 2013 |
| The use of captisol (SBE7-β-CD) in oral solubility-enabling formulations: Comparison to HPβCD and the solubility–permeability interplay A Beig, R Agbaria, A Dahan European Journal of Pharmaceutical Sciences 77, 73-78, 2015 | 61 | 2015 |
| The interaction of nifedipine with selected cyclodextrins and the subsequent solubility–permeability trade-off A Beig, JM Miller, A Dahan European Journal of Pharmaceutics and Biopharmaceutics 85 (3), 1293-1299, 2013 | 60 | 2013 |
| Hydrotropic solubilization of lipophilic drugs for oral delivery: the effects of urea and nicotinamide on carbamazepine solubility–permeability interplay A Beig, D Lindley, JM Miller, R Agbaria, A Dahan Frontiers in Pharmacology 7, 379, 2016 | 58 | 2016 |
| Advantageous solubility-permeability interplay when using amorphous solid dispersion (ASD) formulation for the BCS class IV P-gp substrate rifaximin: simultaneous increase of … A Beig, N Fine-Shamir, D Lindley, JM Miller, A Dahan The AAPS journal 19, 806-813, 2017 | 57 | 2017 |
| Segmental-dependent permeability throughout the small intestine following oral drug administration: Single-pass vs. Doluisio approach to in-situ rat perfusion I Lozoya-Agullo, M Zur, A Beig, N Fine, Y Cohen, M González-Álvarez, ... International journal of pharmaceutics 515 (1-2), 201-208, 2016 | 56 | 2016 |
| Concomitant solubility-permeability increase: vitamin E TPGS vs. amorphous solid dispersion as oral delivery systems for etoposide A Beig, N Fine-Shamir, D Porat, D Lindley, JM Miller, A Dahan European Journal of Pharmaceutics and Biopharmaceutics 121, 97-103, 2017 | 49 | 2017 |
| Toward successful cyclodextrin based solubility-enabling formulations for oral delivery of lipophilic drugs: solubility–permeability trade-off, biorelevant dissolution, and the … N Fine-Shamir, A Beig, M Zur, D Lindley, JM Miller, A Dahan Molecular pharmaceutics 14 (6), 2138-2146, 2017 | 47 | 2017 |
| Striking the optimal solubility–permeability balance in oral formulation development for lipophilic drugs: maximizing carbamazepine blood levels A Beig, JM Miller, D Lindley, A Dahan Molecular pharmaceutics 14 (1), 319-327, 2017 | 38 | 2017 |
| Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres T Li, A Chandrashekar, A Beig, J Walker, JKY Hong, A Benet, J Kang, ... European Journal of Pharmaceutics and Biopharmaceutics 158, 401-409, 2021 | 27 | 2021 |
| Physical–chemical characterization of octreotide encapsulated in commercial glucose-star PLGA microspheres A Beig, L Feng, J Walker, R Ackermann, JKY Hong, T Li, Y Wang, B Qin, ... Molecular Pharmaceutics 17 (11), 4141-4151, 2020 | 24 | 2020 |
| Segmental-dependent intestinal drug permeability: Development and model validation of in silico predictions guided by in vivo permeability values O Wolk, M Markovic, D Porat, N Fine-Shamir, M Zur, A Beig, A Dahan Journal of Pharmaceutical Sciences 108 (1), 316-325, 2019 | 20 | 2019 |
